Catalyst Pharmaceuticals stock price targets established by healthcare equity research analysts hover around thirty-one dollars and fifty cents per share, reflecting definitive corporate acquisition agreements and tender offers valuing the commercial-stage biopharmaceutical enterprise at a substantial premium to support its specialized rare disease treatment portfolio.